By utilizing skills of our dexterous workforce, engaged in manufacturing and supplying of (CAS No. 379270-35-6) high purity Tenofovir alafenamide in Jinan, Shandong, China. Tenofovir alafenamide (INN/USAN; trade name Vemlidy) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF), TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Gilead was awarded FDA approval in November 2016 for the drug Vemlidy.